Study Finds Lower Risk of Severe Infection and Hospitalization with Belimumab Compared to Oral Immunosuppressants
American College of Rheumatology (ACR)New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that the biologic B-cell inhibitor belimumab was associated with a lower risk of severe infections and hospitalizations compared to nonbiologic immunosuppressants.